These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9809537)

  • 1. Nailing down another HIV target.
    Richman DD
    Nat Med; 1998 Nov; 4(11):1232-3. PubMed ID: 9809537
    [No Abstract]   [Full Text] [Related]  

  • 2. T-20 being called "miraculous".
    AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
    [No Abstract]   [Full Text] [Related]  

  • 3. [Fusion proteins in HIV-AIDS treatment].
    Hennemann A
    Med Monatsschr Pharm; 2003 Sep; 26(9):300-2. PubMed ID: 14526613
    [No Abstract]   [Full Text] [Related]  

  • 4. US FDA approves new class of HIV therapeutics.
    Robertson D
    Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
    [No Abstract]   [Full Text] [Related]  

  • 5. New class of medications approved for advance HIV.
    FDA Consum; 2003; 37(3):5. PubMed ID: 12793380
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV fusion inhibitors.
    Pozniak A
    J HIV Ther; 2001 Nov; 6(4):91-4. PubMed ID: 11740409
    [No Abstract]   [Full Text] [Related]  

  • 7. T-20 (Fuzeon) gets priority review.
    AIDS Treat News; 2002 Oct; (384):4-5. PubMed ID: 12434762
    [No Abstract]   [Full Text] [Related]  

  • 8. T-20 continues to look promising.
    AIDS Patient Care STDS; 1999 Dec; 13(12):753. PubMed ID: 10743540
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. T-20 (enfurvirtide, Fuzeon).
    TreatmentUpdate; 2005; 17(1):5-6. PubMed ID: 17225316
    [No Abstract]   [Full Text] [Related]  

  • 10. Fusion inhibitor approved.
    AIDS Patient Care STDS; 2003 May; 17(5):253. PubMed ID: 12816619
    [No Abstract]   [Full Text] [Related]  

  • 11. [New drug class blocks virus-cell fusion. HIV not admitted].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584215
    [No Abstract]   [Full Text] [Related]  

  • 12. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 13. First fusion inhibitor for advanced HIV.
    Am J Nurs; 2003 Jul; 103(7):64F. PubMed ID: 12877130
    [No Abstract]   [Full Text] [Related]  

  • 14. New-Fill on "hold" and open-label for T-20.
    Berger DS
    Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532
    [No Abstract]   [Full Text] [Related]  

  • 15. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 16. Fuzeon data review.
    GMHC Treat Issues; 2003 Mar; 17(3):6. PubMed ID: 12728857
    [No Abstract]   [Full Text] [Related]  

  • 17. Fresh data on new anti-HIV drugs presented in Durban.
    Leibovich M
    Posit Living; 2000 Aug; 9(7):16-7. PubMed ID: 12492026
    [No Abstract]   [Full Text] [Related]  

  • 18. [HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].
    Blasko M
    Dtsch Med Wochenschr; 2003 May; 128(19):1032. PubMed ID: 12774800
    [No Abstract]   [Full Text] [Related]  

  • 19. Enfuvirtide (Fuzeon) for HIV Infection.
    Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195
    [No Abstract]   [Full Text] [Related]  

  • 20. David Reddy--taking HIV therapy to new frontiers. Interview by Pam Das.
    Reddy D
    Lancet Infect Dis; 2003 Feb; 3(2):110-3. PubMed ID: 12560198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.